Table 5.
Baseline Characteristics of US Adults Recommended Antihypertensive Medication According to the ACC/AHA Guideline, 2014 Expert Panel Report, and JNC7 Based on the 2013 to 2016 PINNACLE Registry Data
| Characteristics | ACC/AHA guideline | 2014 Report | Difference between ACC/AHA guideline and 2014 report | JNC7 | Difference between ACC/AHA guideline and JNC7 |
|---|---|---|---|---|---|
| Total No. | 4 266 118 | 3 734 134 | 531 984 | 3 983 633 | 282 485 |
| Age, y | |||||
| Mean±SD | 66.5±13.8 | 66.3±13.9 | 68.1±12.6 | 66.3±13.8 | 68.5±12.7 |
| Median (Q1–Q3) | 68.0 (58.0–76.0) | 67.0 (58.0–76.0) | 69.0 (62.0–77.0) | 68.0 (58.0–76.0) | 70.0 (63.0–77.0) |
| Range (minimum–maximum) | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 | 18.0–100.0 |
| 18–44 | 6.9 | 7.2 | 5.1 | 7.1 | 5.1 |
| 45–54 | 11.5 | 11.9 | 8.3 | 11.7 | 8.4 |
| 55–64 | 21.5 | 22.0 | 17.8 | 22.0 | 14.5 |
| 65–74 | 30.3 | 29.3 | 37.8 | 29.7 | 40.1 |
| ≥75 | 29.8 | 29.6 | 30.9 | 29.6 | 32.0 |
| Sex | |||||
| Men | 50.9 | 51.0 | 50.0 | 50.8 | 51.3 |
| Women | 49.1 | 49.0 | 50.0 | 49.2 | 48.7 |
| Race | |||||
| White | 64.1 | 63.4 | 69.1 | 63.7 | 69.2 |
| Black | 7.5 | 7.7 | 6.3 | 7.7 | 4.9 |
| Other * | 0.5 | 0.5 | 0.4 | 0.5 | 0.3 |
| Missing | 27.9 | 28.4 | 24.2 | 28.1 | 25.6 |
| History of stroke/TIA | 12.0 | 11.9 | 12.1 | 11.8 | 14.8 |
| History of stroke | 9.3 | 9.3 | 10.0 | 9.1 | 12.8 |
| History of TIA | 3.7 | 3.8 | 3.2 | 3.7 | 3.3 |
| Coronary artery disease | 41.6 | 42.3 | 36.8 | 41.5 | 42.9 |
| History of MI | 9.9 | 10.3 | 7.6 | 10.0 | 9.4 |
| History of PCI | 14.2 | 14.6 | 11.3 | 14.3 | 12.8 |
| History of CABG | 7.1 | 7.4 | 4.9 | 7.2 | 5.2 |
| Diabetes | 24.0 | 24.1 | 23.1 | 25.7 | 0.0 |
| Chronic kidney disease | 4.2 | 4.5 | 2.7 | 4.5 | 0.0 |
| Heart failure | 16.4 | 16.7 | 14.0 | 16.4 | 16.5 |
| 10‐y Predicted ASCVD risk, % | |||||
| Mean±SD (N) | 15.5±12.3 (69 294) | 15.5±12.6 (60 416) | 15.3±9.2 (8878) | 15.5±12.5 (64 697) | 14.7±7.1 (4597) |
| Median (Q1–Q3) | 12.4 (6.1–21.7) | 12.1 (5.7–22.0) | 13.6 (9.0–20.1) | 12.2 (5.8–22.0) | 13.6 (10.3–18.9) |
| Range (minimum–maximum) | 0.1–95.1 | 0.1–95.1 | 0.2–86.8 | 0.1–95.1 | 0.2–56.2 |
| <5 | 20.4 | 21.8 | 10.3 | 21.3 | 6.9 |
| 5–<10 | 20.7 | 21.1 | 17.8 | 21.1 | 14.9 |
| 10–<20 | 30.4 | 28.0 | 46.7 | 28.5 | 57.1 |
| ≥20 | 28.6 | 29.1 | 25.2 | 29.1 | 21.1 |
| History of CVD | 52.0 | 52.4 | 49.1 | 51.5 | 59.4 |
Data are given as percentages, unless otherwise indicated. Please note that all adults with hypertension, according to the 2014 expert panel member report definition of hypertension, are recommended treatment with antihypertensive medications. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic CVD; CABG, coronary artery bypass grafting; CVD, cardiovascular disease; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; PINNACLE, Practice Innovation and Clinical Excellence; Q1, quartile 1; Q3, quartile 3; and TIA, transient ischemic attack.
*Defined as combination of any race other than White or Black, including Asian, American Indian/Alaskan Native, Native Hawaiin/ Pacific Islander.